• Aqueous aerosolized mist formulation
  
• Well established safety profile of FDA approved GRAS listed excipients
  
• Ease to administer (small device-MDI)
  
• Almost direct access to highly vascularized surface area for absorption (oropharynx, cheeks and tongue)¹ (No lung deposition)
  
• Rapid onset of action
  
• Expected improvement in compliance
  
• Room temperature stability, convenient to carry and handle
  
• Dose delivery-Uniform throughout the life of vial²

Introduction | Abstract |
Oral Insulin Spray | Study Goal, Method, Research, Conclusions